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Abstract: 
Although physicians are aware of the risks of prescribing long-term off-
label antipsychotics in people with intellectual disability, attempts to 
discontinue often fail. This study aimed to identify potential determinants 
of successful and failed discontinuation. Long-term used off-label 
antipsychotics were tapered off in 14 weeks with 12.5% of baseline dose 
every 2 weeks. Participants from living facilities of intellectual disability 
service providers, aged >6 years with an IQ<70 were eligible to 
discontinue as judged by their physicians. The primary outcome was 
achievement of complete discontinuation at 16 weeks; changes in the 
Aberrant Behavior Checklist (ABC) and its five subscales were secondary 
outcomes. Potential determinants of success or failure to discontinue 
antipsychotics were psychotropic drug use and participants’ living 
circumstances, medical health conditions, severity of behavioral symptoms 
and of neurological side-effects. Of 499 eligible clients 129 were recruited. 
Reason for non-participation were clinicians’ concerns that discontinuation 
might increase challenging behaviors and changes in the clients’ 
environment. Of the 129 participants 61% had completely discontinued 
antipsychotics at 16 weeks, 46% at 28, and 40% at 40 weeks. ABC total 
scores increased in 49% of those with unsuccessful discontinuation at 16 
weeks. Autism, higher dose of antipsychotic drug, higher ABC scores and 
akathisia, and more frequent worsening in health during discontinuation 
were associated with a lower chance of complete discontinuation. Thus, in 
a selected sample of participants in whom the responsible clinician felt that 
discontinuation of antipsychotics could be attempted 40% achieved 
discontinuation. Physicians should try to address patients’ conditions that 
may hamper discontinuation. 
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AN OPEN LABEL DISCONTINUATION TRIAL OF LONG-TERM USED OFF-LABEL ANTIPSYCHOTIC 




Although physicians are aware of the risks of prescribing long-term off-label antipsychotics in people 
with intellectual disability, attempts to discontinue often fail. This study aimed to identify potential 
determinants of successful and failed discontinuation. Long-term used off-label antipsychotics were 
tapered off in 14 weeks with 12.5% of baseline dose every 2 weeks. Participants from living facilities 
of intellectual disability service providers, aged >6 years with an IQ<70 were eligible to discontinue as 
judged by their physicians. The primary outcome was achievement of complete discontinuation at 16 
weeks; changes in the Aberrant Behavior Checklist (ABC) and its five subscales were secondary 
outcomes. Potential determinants of success or failure to discontinue antipsychotics were 
psychotropic drug use and participants’ living circumstances, medical health conditions, severity of 
behavioral symptoms and of neurological side-effects. Of 499 eligible clients 129 were recruited. 
Reason for non-participation were clinicians’ concerns that discontinuation might increase 
challenging behaviors and changes in the clients’ environment. Of the 129 participants 61% had 
completely discontinued antipsychotics at 16 weeks, 46% at 28, and 40% at 40 weeks. ABC total 
scores increased in 49% of those with unsuccessful discontinuation at 16 weeks. Autism, higher dose 
of antipsychotic drug, higher ABC scores and akathisia, and more frequent worsening in health during 
discontinuation were associated with a lower chance of complete discontinuation. Thus, in a selected 
sample of participants in whom the responsible clinician felt that discontinuation of antipsychotics 
could be attempted 40% achieved discontinuation. Physicians should try to address patients’ 
conditions that may hamper discontinuation. 
 
 
Key words: intellectual disability; antipsychotic drugs; off-label use; discontinuation; determinants; 
mental health; Psychopharmacology 
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Individuals with intellectual disability frequently show challenging behavior
1
. Challenging behavior is 
defined as culturally abnormal behavior of such intensity, frequency, or duration that the 
physical safety of the person or others is placed in serious jeopardy, or behavior which is likely to 
seriously limit or deny access to the use of ordinary community facilities. Examples are aggressive or 
irritable behavior, inappropriate sexual behavior, self-injurious behavior and stereotypic behavior. In 
Europe antipsychotics are licensed for the treatment of psychosis and symptoms of severe agitation. 
Besides, the antipsychotic drug risperidone is licensed for the short term treatment of aggressive 
behavior in adults with intellectual disability and in children aged over five years. In the US 
risperidone and aripiprazole are also labelled for the treatment of irritability associated with autism. 
Antipsychotics are often off-label prescribed for long-term treatment of challenging behavior in 
people with intellectual disability, although there is insufficient evidence for their effectiveness for 
this treatment target and an increased risk of side-effects in this population
1
 . 
There is growing awareness among clinicians and policy makers that long-term off-label use of 
psychotropic drugs for challenging behaviors should be avoided as much as possible . Yet, the 
prevalence of psychotropic drug use remains high
2
. In a recent study almost 30% of individuals with 
intellectual disability used psychotropic medication, of which 95% were off-label prescriptions. 
however, clinicians decided just in half of these cases that their clients were eligible to discontinue 
the long-term off-label use
3
. Main reasons for deciding against discontinuation were fears for 
increasing restlessness, aggression, and other behavioral disturbances, the presence of autism, and 
previously unsuccessful discontinuation attempts. Furthermore, environmental factors, like 
unfavorable living circumstances, changes in living situations or recent life events were main issues 
not to discontinue. Indeed, some studies have shown that life events and changes in socio-
demographic conditions were associated with challenging behavior and mental ill-health
,4,5,6
. 
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Although there is a substantial proportion of long-term off-label antipsychotic drug users in which 
discontinuation is successful, attempts to discontinue may fail because of behavioral worsening due 
to a variety of yet unclear causes
7
. Potential causes may lay in the onset of previously suppressed 
symptoms of mental or physical disorders. Such symptoms of mental disorders in people with 
intellectual disability may be misinterpreted as maladaptive behavior. In turn, physicians may react 
with changes in medication, most often by again increasing dosages and/or adding new psychotropic 
medications
8
. Also physical symptoms of chronic or acute medical conditions, including side-effects 
of medication often remain unrecognized and may present as behavioral disturbance. Furthermore, 
neurological withdrawal symptoms may occur and hinder successful discontinuation, as these may 
also express as behavioral symptoms and may be wrongly interpreted, e.g., dyskinesia as restlessness 
and akathisia as hyperactivity. Indeed, in a previous study caregivers and physicians disagreed in the 
identification of symptoms of dyskinesia and akathisia
9
. Last, unsuccessful discontinuation in clinical 
practice is often attributed to changes in environmental circumstances or unfavorable living 
circumstances, which may cause clients to react with maladaptive behavior. 
Thus, off-label inappropriate antipsychotic drug use should be reduced, while causes of behavioral 
worsening during discontinuation should be identified and appropriately treated and managed. 
There is need for more insight in factors that may hinder successful discontinuation of long-term off-
label used antipsychotics for challenging behavior. Therefore, we set up a study in which we 
investigated changes in challenging behavior upon gradual discontinuation of antipsychotics as well 
as the influence of client-related factors and environmental circumstances as potential determinants 
for the chance of achieving complete discontinuation.  
 
METHODS 
Design and setting 
We combined data of two open label discontinuation studies; (1) discontinuation of long term used 
risperidone prescribed for challenging behavior (Netherlands Trial Register NTR5509) and (2) a 
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discontinuation study involving all other antipsychotics (NTR5519). Potential participants had 
received a treatment proposal from their physician involving an attempt to discontinue 
antipsychotics. All legal representatives of participants had provided written informed consent. 
We prospectively investigated the influence of factors potentially associated with successful 
discontinuation, including changes in environmental circumstances. Study settings were living 
facilities of six care providing organizations. Two of the six organizations also provided data for the 
open label discontinuation of risperidone. 
 
Study population 
Eligible participants could be of any sex or ethnicity, were aged ≥ 6 years, were functioning below an 
IQ level of 70, and had used one or more antipsychotics for more than one year for challenging 
behavior.  Excluded were subjects with schizophrenia, a bipolar disorder, or an affective psychosis 
according to the Diagnostic Statistic Manual (DSM)-IV TR or International Code of Diseases (ICD) -10. 
Another exclusion criterion was an unsuccessful attempt to discontinue the antipsychotics in the 
previous 6 months, as another attempt to discontinue after a short frame would be unlikely to be 
successful. Use of other psychotropic drugs was not an exclusion criterion. 
 
Outcomes 
The primary outcome measure was achievement of complete discontinuation at 16 weeks. 
Secondary outcome measures were achievement of complete discontinuation at the time points of 
28 weeks and 40 weeks; and changes in the Aberrant Behavior Checklist (ABC) and its five subscales 
i.e., irritability, lethargy, stereotypic behavior, hyperactivity, and inadequate speech. The ABC is a 
standardized, validated scale developed to measure severity of challenging behaviors and effects of 
treatment on the behavior
,10,11
. The ABC was completed by the main caregiver. We defined changes 
of > 8 points in ABC total scores (0.33 SD) as clinically relevant. 
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Potential baseline determinants were psychotropic drug use characteristics (dosage of antipsychotic 
drug, use of >1 antipsychotic simultaneously, use of other psychotropic, and/or anti-epileptic drugs), 
participant characteristics (severity of behavioral symptoms as measured with the ABC, presence or 
history of medical conditions, and presence and severity of extrapyramidal and autonomic 
neurological side-effects), and environmental circumstances (the presence or history of life events). 
Potential determinants during discontinuation were the occurrence of new health problems and/or 
worsening in health or chronic medical conditions, changes in living situation and life events, and the 
severity of behavioral, extrapyramidal and autonomic symptoms as measured at the different time 
points of data collection during discontinuation. 
For assessment of extrapyramidal symptoms we used items 1 through 9 of the Abnormal Involuntary 
Movement Scale (AIMS), the Barnes akathisia objective symptoms, subjective symptoms and burden 
scale (BARS), and motor items 20, 21, 22, and 31 of the Unified Parkinson Scale (UPDRS). Autonomic 
symptoms were measured by the Scale for Outcomes in Parkinson‘s disease-Autonomic Symptoms 
(SCOPA-AUT), which we slightly adapted by adding two questions on fecal and urine continence. All 
these scales were completed by a trained research assistant. 
To assess worsening in health during the study period we counted the number of times participants 
experienced new health problems as reported by their caregivers, the number of consultations of 
participants with their general practitioner, intellectual disability physician, and/or other specialist, 
the number of new medication prescriptions or dose changes, and the number of new non-




Discontinuation was done by intellectual disability physicians or general practitioners according to a 
scheduled discontinuation time frame of 14 weeks duration. The discontinuation schedule was based 
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at our previous study, in which tapering of antipsychotic drugs in a relatively short time frame could 
safely be done
12
. The study was performed as part of regular clinical care. This implied that 
participants remained in the study and data collection was continued to the end of the study follow-
up when physicians decided the participant should no longer taper off the antipsychotic drug, should 
taper off in another time schedule, or should use a higher dose. 
Participants were included from 1
st
 of January 2015 till 1
st
 of February 2016. Outcome measures were 
collected at baseline, at 4, 8, 12, and 16 weeks (during the discontinuation period per protocol) and 
at 22, 28 and 40 weeks (follow-up) after the first dose reduction.  
 
Sample size  
The sample size was based on potential associations of determinants with achievement of complete 
discontinuation by means of logistic regression analyses. With a total of 12 variables and a small 
effect size of 0.15, a power of 0.80 and a probability level of 0.05 a sample size of 127 was required.  
 
Statistical analyses 
We used Statistical Package for the Social Sciences (SPSS) version 23 for statistical analyses. The main 
study parameter was achievement of complete discontinuation at 16 weeks (i.e., 2 weeks after the 
scheduled complete discontinuation); we also considered achievement of discontinuation at two 
follow-up time points, i.e., 28 and 40 weeks after the first dose reduction. We distinguished groups 
with complete and incomplete discontinuation status at the three different time points.  
With paired sampled t-tests, we compared baseline severity of behavioral measures and symptoms 
of neurological side-effects with these at 16, 28, and 40 weeks.  
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With independent sample T-test for continuous variables and Pearson Chi-square test for categorical 
variables we compared participants’ characteristics of those with complete and those with 
incomplete discontinuation at baseline, 16, 28, and 40 weeks, and of those who used typical versus 
atypical antipsychotics at baseline and 16 weeks. 
In case of non-normal distribution of continuous variables we used the Wilcoxon signed rank test for 
paired sampled test and Mann-Whitney U test for independent sampled test. 
To select variables for the multivariate regression analyses we used univariate logistic regression 
analyses to investigate potential associations of participants characteristics (sex, age, severity of 
intellectual disability, living situation) and determinants with the odds for complete discontinuation 
at 16, 28, and 40 weeks, respectively. Subsequently, we used variables with a p-value< 0.1 in 
multivariate logistic analyses. Here, we used scores of the continuous variables ABC, AIMS, BARS, and 
UPDRS at the previous time point as baseline determinants for the time point in step wise regression 
analyses, e.g., ABC score at 16 weeks as baseline value for ABC at 28 weeks. 
Finally, we investigated potential associations of neurological side-effects and/or withdrawal 
symptoms with behavioral symptoms as measured with the ABC subscales in univariate regression 
analyses at the different time points. 
A p-value of <0.05 was used to indicate significant differences. 
 
RESULTS 
We included 129 participants. Figure 1 shows the flow chart of the study.  
Table 1a shows the baseline participant characteristics, including the presence and severity of 
extrapyramidal and autonomic symptoms associated with antipsychotic drug use. Table 1b shows the 
psychotropic drug use of participants. Atypical antipsychotic medication was prescribed in 35% of 
participants. There was no significant difference in mean baseline dosage between participants who 
used atypical versus typical antipsychotic drugs. Furthermore, there were no significant differences in 
achievement of complete discontinuation, in severity of behavioral symptoms as measured with the 
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ABC, and in severity of extrapyramidal and autonomic symptoms during discontinuation at the time 
point of 16 weeks after the first dose reduction (time point of scheduled discontinuation) between 
these groups. 
Achievement of complete discontinuation 
Figure 2 shows the numbers of participants who achieved complete discontinuation of their long-
term off-label antipsychotic drug use at 16 weeks (discontinuation per protocol), and at 28 and 40 
weeks after the first dose reduction.  
Of the 79 participants who completely discontinued antipsychotics at 16 weeks, 25 participants 
(32%) restarted the use of antipsychotics between 16 and 28 weeks. Of those 60 participants who 
were completely off antipsychotics at 28 weeks, 8 (13%) restarted the use between 28 and 40 weeks. 
Of the 49 participants who incompletely discontinued at 16 weeks, 6 (12%) yet discontinued 
between 16 and 28 weeks. Of the 67 participants who had incompletely discontinued or had 
restarted the use at 28 weeks 3 (4%) were completely off antipsychotics at 40 weeks. 
 
Behavioral outcomes, neurological side-effects, and worsening in health during discontinuation 
At 16 weeks 46 participants (36%) showed a decrease and 35 participants (27%) a clinically relevant 
increase of ABC total scores (>8 points) compared to baseline. In 32 participants there were no 
clinically relevant differences in ABC scores at 16 weeks compared to baseline. ABC data of 16 
participants was missing in the medical records. In those with incomplete discontinuation there was 
more often a clinically relevant increase in ABC total scores than in those with complete 
discontinuation (49% versus 21%; Pearson Chi-square=10.1; p=0.006). 
Table 2 shows the mean, median, and confidence interval of ABC total and subscale scores for both 
groups at 16 weeks after the first dose reduction (discontinuation per protocol).  
The group of participants who had completely discontinued showed a significant decrease in severity 
of behavioral symptoms as measured with the ABC total score and ABC subscale 2 at the time points 
of 16, 28, and 40 weeks, and of ABC subscale 1 and ABC subscale 4 at 40 weeks. Also, there was a 
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decrease in parkinsonism in those with complete discontinuation. In those with incomplete 
discontinuation there was a significant decrease of akathisia at 40 weeks and a significant  increase in 
severity of autonomic symptoms at 16 weeks. 
See Supplemental table 1 for all within groups comparisons of severity of behavioral and of 
neurological symptoms before (baseline) and after discontinuation of antipsychotics at the time 
points 16, 28, and 40 weeks of participants who had completely and incompletely discontinued at 
these time points. 
Worsening in health occurred in 76 of the 129 participants The worsening in health included 
temporary ill-health conditions and exacerbations of chronic mental and somatic conditions, and 
related treatments, as reported by the main caregiver or as reported by physicians. Examples are 
pain caused by muscle spasms in cerebral palsy followed by physiotherapy, abdominal pain due to 
constipation followed by prescription of laxatives, heart burn, infectious diseases, increased severity 
of sleep problems or symptoms of anxiety, and staff’s perceptions of clients feeling uncomfortable. 
The mean number of a worsening in health between baseline and 40 weeks was 2.7. These were 
reports of caregivers in 28%, consultations of the general practitioner in 21% (mostly related to ill-
health and the chronic medical conditions), prescription of new medication or dose changes in 22% 
(mostly related to consultation of general practitioner or intellectual disability (ID) physician), 
consultation of the ID physician in 15% (of these were 45% for somatic conditions and 55% for 
mental health conditions), consultation of a medical specialist in 7% (often for chronic medical 
conditions), and non-pharmaceutical treatments in 6%.  
Changes in environmental circumstances occurred in 68 participants. The mean number of changes 
between baseline and 40 weeks was 1.3. The changes were mostly in daily activities, in composition 
of the residential group, in the main caregiver, and moving to a new residence.  
 
Differences between groups achieving complete and incomplete discontinuation  
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Participants who had achieved complete discontinuation had a less severe intellectual disability, less 
often presence of autism and chronic neurological conditions, less severe parkinsonism, had less 
often worsening in health during the study period, and had more often a history of dermatoses and 
surgical conditions; with regard to psychotropic drug use they used a lower baseline dosage and used 
less often > 1 antipsychotic simultaneously. They also experienced fewer severe behavioral 
symptoms as measured with the ABC. See Supplemental table 2 for all differences between 
participants with complete versus those with incomplete discontinuation at the time points 16, 28, 
and 40 weeks after the first dose reduction.  
 
Determinants of successful discontinuation at the time points 16, 28, and 40 weeks 
A number of participant characteristics and determinants were associated with the chance of 
complete discontinuation at the different time points. No history of dermatoses, no history of 
surgical conditions, no stressful family conditions, higher dose of antipsychotic drug, higher scores of 
ABC, and higher scores of akathisia were all associated with a lower chance of complete 
discontinuation. Absence of autism, no recent hospitalization, and no use of more than on 
antipsychotic drug simultaneously were associated with higher chance of complete discontinuation. 
Furthermore, more frequent worsening in health during discontinuation was associated with lower 
chance of complete discontinuation. 
Table 3 presents the results of multivariate logistic regression analyses at the different time points, 
with achievement of complete discontinuation as the dependent variable. As independent variables 
we included those variables with p-values <0.1 in univariate analyses (see Supplemental table 3) 
Because we were interested in the influence of neurological (withdrawal) symptoms on the severity 
of challenging behavior we also investigated potential associations of extrapyramidal and autonomic 
symptoms with ABC subscales. Higher ratings of ABC subscale lethargy were associated with more 
severe akathisia and autonomic dysregulation, and higher ratings of ABC subscale stereotypy and of 
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In this open label discontinuation study 61% of participants were able to discontinue off-label 
antipsychotics completely in 16 weeks. At follow-up, three months later (28 weeks after the first 
dose reduction) 46% of participants were still completely off their antipsychotic medication, and at 
40 weeks follow-up 40%. These results are in line with other discontinuation studies
7
 but somewhat 
better than those in our previous study in which 43% achieved complete discontinuation and 36% 
were still off antipsychotic medication three months later
12
.  
The severity of behavioral symptoms as assessed with the ABC total and subscales had decreased in 
those participants who were completely off medication at all three time points, and had not changed 
significantly in those who had not achieved full discontinuation. These of improved behavioral 
symptoms in those achieving complete discontinuation and on average no change in those with 
incomplete discontinuation confirm our previous findings
12
. Furthermore, in general, in both groups 
there were individual participants with an increase or decrease in severity of behavioral symptoms 
during discontinuation.  
Results with regard to the course of neurological side-effects were mixed. On the one hand there was 
a decrease in parkinsonism in those with complete discontinuation, on the other hand a decrease in 
akathisia in those with incomplete discontinuation at 40 weeks. The decrease in akathisia in those 
participants who still used antipsychotic drugs may be explained by the potential of these agents to 
mask this extrapyramidal symptom or by the disappearance of withdrawal akathisia
13
 . Autonomic 
symptoms increased in those having incompletely discontinued at 16 weeks. This may have been 
caused by again increasing the dosage r additional prescriptions of psychotropic drugs following the 
behavioral disturbances which had led to termination of the discontinuation trajectory.  
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 The present study indicated some determinants which might help to predict whether 
discontinuation will be successful. The presence of autism, akathisia, higher ABC scores, and more 
frequent worsening in health during discontinuation were clearly associated with lower odds of 
successful discontinuation. In people with intellectual disability co-morbid mental disorders, 
neurological side-effects of antipsychotics and ill-health conditions may express as behavioral 
symptoms, which may be difficult to manage. Indeed, more severe dyskinesia, akathisia, and 
autonomic symptoms were associated with higher scores on the ABC subscales lethargy, stereotypy, 
and hyperactivity. When underlying causes of maladaptive behaviors are not recognized, appropriate 
treatments will be lacking, and the severity of behavioral symptoms may increase, which in turn may 
hinder successful discontinuation. The commonly accepted idea that changes in environmental 
circumstances should be a reason not to start or even to stop antipsychotic discontinuation 
trajectories could not be confirmed, given no association between changes in living circumstances 
and life events with lower chance of successful discontinuation.  
 
Strengths and limitations 
A strength of the present study was that it reflects discontinuation in clinical practice. We took the 
influence of negative changes in health conditions and environmental circumstances into 
consideration. However, recruitment of participants was difficult. In only half of cases physicians 
judged their clients with off-label antipsychotic drug use were eligible to discontinue, and of those 
just 26% consented to participate in the study. Fear of clinicians, caregivers, and legal representatives 
for behavioral worsening were main reasons not to discontinue. McNamara et al (2017)
14
 also 
encountered major recruitment problems in their double blind randomized controlled 
discontinuation trial of risperidone used for challenging behaviors. They suggested that lack of 
alternative behavioral interventions to manage the potential re-emergence of challenging behaviors 
of clients may be reasons for the poor recruitment. 
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Another limitation of this study was missing data which reduced the available cases for multivariate 
analyses. Therefore, the results of this study should be confirmed in larger scale studies. However, 
the sample size was large enough to assess associations in univariate analyses reliably and we think 
the results have clinical importance and add to the knowledge in ongoing off-label antipsychotic drug 
use in people with intellectual disability. The open label study design is another limitation, although it 
does reflect discontinuation in clinical practice which is also typically open label. Also, no correction 
for multiple testing was done, to reduce the risk of type 2 errors. However, we cannot exclude that 
some results may have been spurious. Last, because the study took place in living facilities of 
congregated care centers, in a selected sample, the results may not be generalizable to people with 
intellectual disability who live in the community and to clients not eligible to discontinue according to 
their clinicians’ judgements.  
 
CONCLUSIONS/CLINICAL AND RESEARCH IMPLICATIONS 
Forty percent of participants with intellectual disability who were judged by their responsible 
clinicians to be eligible for a withdrawal trial of their long-term off-label antipsychotic drugs were 
able to discontinue in a time frame of approximately four to seven months with on average no 
behavioral worsening.  
We identified a number determinants explaining failure to achieve complete discontinuation with 
clear clinical implications. Especially worsening in chronic medical conditions or temporary ill-health 
conditions in clients, which were negatively associated with successful discontinuation should be 
addressed appropriately and should be no reason to stop the discontinuation trajectory. Also, the 
presence of neurological side-effects should be carefully examined and appropriately managed, since 
these symptoms were associated with higher severity of maladaptive behavior, which in turn was 
associated with a higher chance of failed discontinuation. Finally, the presence of autism spectrum 
disorder, which was also associated with failed discontinuation, perhaps indicating that 
antipsychotics are more effective in those with autism spectrum disorder. 
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Because just over 25% of eligible participants took part in the study, we ought to be cautious in 
drawing final conclusions as results may not be generalizable to the whole population using long 
term antipsychotics; however, this low percentage of those willing to attempt discontinuation 
reflects clinical reality. Larger scale studies in various settings of intellectual disability care are 
needed to confirm our results and to investigate which treatments should be offered in case of 
unsuccessful attempts to discontinue off-label antipsychotics. 
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AN OPEN LABEL DISCONTINUATION TRIAL OF LONG-TERM USED OFF-LABEL ANTIPSYCHOTIC 




Although physicians are aware of the risks of prescribing long-term off-label antipsychotics in people 
with intellectual disability, attempts to discontinue often fail. This study aimed to identify potential 
determinants of successful and failed discontinuation. Long-term used off-label antipsychotics were 
tapered off in 14 weeks with 12.5% of baseline dose every 2 weeks. Participants from living facilities 
of intellectual disability service providers, aged >6 years with an IQ<70 were eligible to discontinue as 
judged by their physicians. The primary outcome was achievement of complete discontinuation at 16 
weeks; changes in the Aberrant Behavior Checklist (ABC) and its five subscales were secondary 
outcomes. Potential determinants of success or failure to discontinue antipsychotics were 
psychotropic drug use and participants’ living circumstances, medical health conditions, severity of 
behavioral symptoms and of neurological side-effects. Of 499 eligible clients 129 were recruited. 
Reason for non-participation were clinicians’ concerns that discontinuation might increase 
challenging behaviors and changes in the clients’ environment. Of the 129 participants 61% had 
completely discontinued antipsychotics at 16 weeks, 46% at 28, and 40% at 40 weeks. ABC total 
scores increased in 49% of those with unsuccessful discontinuation at 16 weeks. Autism, higher dose 
of antipsychotic drug, higher ABC scores and akathisia, and more frequent worsening in health during 
discontinuation were associated with a lower chance of complete discontinuation. Thus, in a selected 
sample of participants in whom the responsible clinician felt that discontinuation of antipsychotics 
could be attempted 40% achieved discontinuation. Physicians should try to address patients’ 
conditions that may hamper discontinuation. 
 
 
Key words: intellectual disability; antipsychotic drugs; off-label use; discontinuation; determinants; 
mental health; Psychopharmacology 
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Nowadays, Individuals with intellectual disability frequently show challenging behavior
1
. Challenging 
behavior is defined as culturally abnormal behavior of such intensity, frequency, or duration that the 
physical safety of the person or others is placed in serious jeopardy, or behavior which is likely to 
seriously limit or deny access to the use of ordinary community facilities. Examples are aggressive or 
irritable behavior, inappropriate sexual behavior, self-injurious behavior and stereotypic behavior. In 
Europe antipsychotics are licensed for the treatment of psychosis and symptoms of severe agitation. 
Besides, the antipsychotic drug risperidone is licensed for the short term treatment of aggressive 
behavior in adults with intellectual disability and in children aged over five years. In the US 
risperidone and aripiprazole are also labelled for the treatment of irritability associated with autism. 
Antipsychotics are often off-label prescribed for long-term treatment of challenging behavior in 
people with intellectual disability, although there is insufficient evidence for their effectiveness for 
this treatment target and an increased risk of side-effects in this population
1
 . 
tThere is growing awareness among clinicians and policy makers idea that long-term off-label use of 
psychotropic drugs for challenging behaviors in people with intellectual disability should be avoided 
as much as possible  has become more and more accepted by clinicians and policy makers. Yet, the 
prevalence of psychotropic drug use remains high
21
. In a recent study we showed a prevalence of 
antipsychotic drug use of almost 30% of individuals with intellectual disability used psychotropic 
medication, of which 95% were off-label prescriptions. ; however, clinicians decided just in half of 
these cases that their clients were eligible to discontinue the long-term off-label use
32
. Main reasons 
for deciding against discontinuation Clinicians indicated thatwere fears for increaseing in 
restlessness, aggression, and other behavioral disturbances, the presence of autism, and previously 
unsuccessful discontinuation attempts were main reasons not to discontinue. Furthermore, 
environmental factors, like unfavorable living circumstances, changes in living situations or recent life 
events were main issues not to discontinue. Indeed, some studies have shown that life events and 
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Although there is a substantial proportion of long-term off-label antipsychotic drug users in which 
discontinuation is successful, attempts to discontinue may fail because of behavioral worsening due 
to a variety of yet unclear causes
76
. Potential causes may lay in the onset of previously suppressed 
symptoms of mental or physical disorders. Such symptoms of mental disorders in people with 
intellectual disability may be misinterpreted as maladaptive behavior. In turn, physicians may react 
with changes in medication, most often by again increasing dosages and/or adding new psychotropic 
medications
87
. Also physical symptoms of chronic or acute medical conditions, including side-effects 
of medication often remain unrecognized and may present as behavioral disturbance. Furthermore, 
neurological withdrawal symptoms may occur and hinder successful discontinuation, as these may 
also express as behavioral symptoms and may be wrongly interpreted, e.g., dyskinesia as restlessness 
and akathisia as hyperactivity. Indeed, in a previous study we found a disagreement between 
caregivers and physicians disagreed in the identification of symptoms of dyskinesia and akathisia
98
. 
Last, In clinical practice causes of unsuccessful discontinuation in clinical practice areis often 
attributed to changes in environmental circumstances or unfavorable living circumstances, which 
may cause clients to react with maladaptive behavior. 
Thus, on the one hand off-label inappropriate antipsychotic drug use should be reduced, while on the 
other hand causes of behavioral worsening during discontinuation should be identified and 
appropriately treated and managed. There is need for more insight in factors that may hinder 
successful discontinuation of long-term off-label used antipsychotics for challenging behavior. 
Therefore, we set up a study in which we investigated the results of discontinuation of antipsychotic 
medication, changes in challenging behavior upon gradual discontinuation of antipsychotics andas 
well as the influence of client-related factors and environmental circumstances as potential 
determinants for the chance of achieving complete discontinuation.  
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Design and setting 
We combined data of two open label discontinuation studies; (1) discontinuation of long term used 
risperidone prescribed for challenging behavior (Netherlands Trial Register NTR5509) and (2) a 
discontinuation study involving all other antipsychotics The study had beenapproved by the Medical 
Ethical Committee University Groningen, METc 2014/402 and is registered in the Netherlands 
National Trial Register,  (NTR5519). Potential participants had received a treatment proposal from 
their physician involving an attempt to discontinue antipsychotics. All legal representatives of 
participants had provided written informed consent. 
Design and setting  
This study investigated determinants of successful achievement of discontinuation of antipsychotics 
and used data of an open label discontinuation trial of long-term used antipsychotics for challenging 
behaviors plus data on open label discontinuation of risperidone (NTR5519 excludes use of 
risperidone). We prospectively investigated the influence of participants-related factors that were 
potentially associated with successful discontinuation, including changes in environmental 
circumstances. Study settings were living facilities of six care providing organizations. Two of the six 
organizations also provided data on for the open label discontinuation of risperidone. 
 
Study population 
Eligible participants could be of any sex or ethnicity, were aged ≥ 6 years, were functioning below an 
IQ level of 70, and had used one or more antipsychotics for more than one year for challenging 
behavior.  Excluded were sSubjects with schizophrenia, a bipolar disorder, or an affective psychosis 
according to the Diagnostic Statistic Manual (DSM)-IV TR or International Code of Diseases (ICD) -10 
were excluded. Another exclusion criterion was an unsuccessful attempt to discontinue the 
antipsychotics in the previous 6 months, as another attempt to discontinue after a short frame would 
be unlikely to be successful. Use of other psychotropic drugs was not an exclusion criterion. 
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The primary outcome measure was achievement of complete discontinuation at 16 weeks. 
Secondary outcome measures were achievement of complete discontinuation at the time points of 
28 weeks and 40 weeks; and changes in the Aberrant Behavior Checklist (ABC) and its five subscales 
i.e., irritability, lethargy, stereotypic behavior, hyperactivity, and inadequate speech. The ABC is a 
standardized, validated scale developed to measure severity of challenging behaviors and effects of 
treatment on the behavior
9,10,11
. The ABC was completed by the main caregiver. We defined changes 
of > 8 points in ABC total scores (0.33 SD) as clinically relevant. 
 
Determinants  
Potential baseline determinants were psychotropic drug use characteristics (dosage of antipsychotic 
drug, use of >1 antipsychotic simultaneously, use of other psychotropic, and/or anti-epileptic drugs), 
participant characteristics (severity of behavioral symptoms as measured with the ABC, presence or 
history of medical conditions, and presence and severity of extrapyramidal and autonomic 
neurological side-effects), and environmental circumstances (the presence or history of life events). 
Potential determinants during discontinuation were the occurrence of new health problems and/or 
worsening in health or chronic medical conditions, changes in living situation and life events, and the 
severity of behavioral, extrapyramidal and autonomic symptoms as measured at the different time 
points of data collection during discontinuation. 
For assessment of extrapyramidal symptoms we used items 1 through 9 of the Abnormal Involuntary 
Movement Scale (AIMS), the Barnes akathisia objective symptoms, subjective symptoms and burden 
scale (BARS), and motor items 20, 21, 22, and 31 of the Unified Parkinson Scale (UPDRS). Autonomic 
symptoms were measured by the Scale for Outcomes in Parkinson‘s disease-Autonomic Symptoms 
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(SCOPA-AUT), which we slightly adapted by adding two questions on fecal and urine continence. All 
these scales were completed by a trained research assistant. 
To assess worsening in health during the study period we counted the number of times participants 
experienced new health problems as reported by their caregivers, the number of consultations of 
participants with their general practitioner, intellectual disability physician, and/or other specialist, 
the number of new medication prescriptions or dose changes, and the number of new non-




Discontinuation was done by intellectual disability physicians or general practitioners according to a 
scheduled discontinuation time frame of 14 weeks duration. The discontinuation schedule was based 
at our previous study, in which we found tapering of antipsychotic drugs in a relatively short time 
frame can could safely be done
121
. The study was performed as part of regular clinical care. This 
means implied that participants remained in the study and data collection was continued to the end 
of the study follow-up when physicians decided the participant should no longer taper off the 
antipsychotic drug, should taper off in another time schedule, or should use a higher dose, 
participants remained in the study and data collection was continued to the end of the study follow-
up. 
Participants were included from 1
st
 of January 2015 till 1
st
 of February 2016. Outcome measures were 
collected at baseline, at 4, 8, 12, and 16 weeks (during the discontinuation period per protocol) and 
at 22, 28 and 40 weeks (follow-up) after the first dose reduction.  
 
Sample size  
The sample size calculation was based on potential associations of determinants with achievement of 
complete discontinuation by means of logistic regression analyses. With a total of 12 variables and a 
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We used Statistical Package for the Social Sciences (SPSS) version 23 for statistical analyses. The main 
study parameter was achievement of complete discontinuation at 16 weeks (i.e., 2 weeks after the 
scheduled complete discontinuation); we also considered achievement of discontinuation at two 
follow-up time points, i.e., 28 and 40 weeks after the first dose reduction. We distinguished groups 
with complete and incomplete discontinuation status at the three different time points.  
With paired sampled t-tests, we compared baseline severity of behavioral measures and symptoms 
of neurological side-effects with these at 16, 28, and 40 weeks.  
With independent sample T-test for continuous variables and Pearson Chi-square test for categorical 
variables we compared participants’ characteristics of those with complete and those with 
incomplete discontinuation at baseline, 16, 28, and 40 weeks, and of those who used typical versus 
atypical antipsychotics at baseline and 16 weeks. 
In case of non-normal distribution of continuous variables we used the Wilcoxon signed rank test for 
paired sampled test and Mann-Whitney U test for independent sampled test. 
To select variables for the multivariate regression analyses we used With univariate logistic 
regression analyses towe investigated potential associations of participants characteristics 
(gendersex, age, severity of intellectual disability, living situation) and determinants with the odds for 
complete discontinuation at 16, 28, and 40 weeks, respectively. Subsequently, we used variables 
with a p-value< 0.1 in multivariate logistic analyses. Here, we used scores of the continuous variables 
ABC, AIMS, BARS, and UPDRS at the previous time point as baseline determinants for the time point 
in step wise regression analyses, e.g., ABC score at 16 weeks as baseline value for ABC at 28 weeks. 
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Finally, we investigated potential associations of neurological side-effects and/or withdrawal 
symptoms with behavioral symptoms as measured with the ABC subscales in univariate regression 
analyses at the different time points. 
A p-value of <0.05 was used to indicate significant differences. 
 
RESULTS 
We included 129 participants. Figure 1 shows the flow chart of the study.  
Table 1a shows the baseline participant characteristics, including the presence and severity of 
extrapyramidal and autonomic symptoms associated with antipsychotic drug use. Table 1b shows the 
psychotropic drug use of participants. Atypical antipsychotic medication was prescribed in 35% of 
participants. There was no significant difference in mean baseline dosage between participants who 
used atypical versus typical antipsychotic drugs. Furthermore, there were no significant differences in 
achievement of complete discontinuation, in severity of behavioral symptoms as measured with the 
ABC, and in severity of extrapyramidal and autonomic symptoms during discontinuation at the time 
point of 16 weeks after the first dose reduction (time point of scheduled discontinuation) between 
these groups. 
Achievement of complete discontinuation 
Figure 2 shows the numbers of participants who had achieved completely and incompletely 
discontinuation ofed their long-term off-label antipsychotic drug use at 16 weeks (discontinuation 
per protocol), and at 28 and 40 weeks after the first dose reduction, including those participants who 
had restarted their use and who had yet discontinued between the time points during follow-up.  
Of the 79 participants who had completely discontinued antipsychotics at 16 weeks, 25 
hadparticipants (32%) restarted their use of antipsychotics between 16 and 28 weeks. 25 participants 
ABC total scores decreased in 8 participants , increased in 8 participants, and remained the same in 4 
participants; data of 5 participants were missing. In the 54 participants who were still off 
antipsychotics at 28 weeks ABC total scores decreased in 22 participants, increased in 11 
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participants, and did not change in 16 participants; data of 5 participants were missing. In all but two 
cases (see Figure 1) the missing data was caused by incomplete medical and pharmaceutical record 
keeping. In Of those 2560 participants who were completely off antipsychotics at 28 weeks, 8 (13%) 
restarted the use between 28 and 40 weeks. Of the 49 participants who incompletely discontinued at 
16 weeks, 6 (12%) yet discontinued between 16 and 28 weeks. Of the 67 participants who had 
incompletely discontinued or had restarted the use at 28 weeks 3 (4%) were completely off 
antipsychotics at 40 weeks. 
 
Behavioral outcomes, neurological side-effects, and worsening in health during discontinuation 
At 16 weeks 46 participants (36%) showed a decrease and 35 participants (27%) a clinically relevant 
increase of ABC total scores (>8 points) compared to baseline. In 32 participants there were no 
clinically relevant differences in ABC scores at 16 weeks compared to baseline. scores were similar 
and ABC data of 16 participants was missing in the medical records. In those with incomplete 
discontinuation there was more often a clinically relevant increase in ABC total scores than in those 
with complete discontinuation (49% versus 21%; Pearson Chi-square=10.14; p=0.006). 
Table 2 shows the mean, median, and confidence interval of ABC total and - subscale scores for both 
groups at 16 weeks after the first dose reduction (discontinuation per protocol).  
The group of participants who had completely discontinued showed a significant decrease in severity 
of behavioral symptoms as measured with the ABC total score and ABC subscale 2 at the time points 
of 16, 28, and 40 weeks, and of ABC subscale 1 and ABC subscale 4 at 40 weeks. Also, there was a 
decrease in parkinsonism in those with complete discontinuation. In those with incomplete 
discontinuation we foundthere was a significant decrease of akathisia at 40 weeks and a significant n 
increase in severity of autonomic symptoms at 16 weeks. 
See Supplemental table 1 for all within groups comparisons of severity of behavioral and of 
neurological symptoms before (baseline) and after discontinuation of antipsychotics at the time 
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points 16, 28, and 40 weeks of participants who had completely and incompletely discontinued at 
these time points. 
Worsening in health occurred in 76 of the 129 participants; the mean number of a worsening in 
health between baseline and 40 weeks was 2.7.  The Health worsenings in health included temporary 
ill-health conditions and exacerbations of worsening in chronic mental and somatic conditions, and 
related treatments, as recordedreported by the main caregivers or as reported by physicians. 
Examples are pain caused by muscle spasms in cerebral palsy followed by physiotherapy, abdominal 
pain due to constipation followed by prescription of laxatives, heart burn, infectious diseases, 
increased severity of sleep problems or symptoms of anxiety, and staff’s perceptions of clients 
feeling uncomfortable. The mean number of a worsening in health between baseline and 40 weeks 
was 2.7. These were reports of caregivers in 28%, consultations of the general practitioner in 21% 
(mostly related to ill-health and the chronic medical conditions), prescription of new medication or 
dose changes in 22% (mostly related to consultation of general practitioner or intellectual disability 
(ID) physician), consultation of the ID physician in 15% (of these were 45% for somatic conditions and 
55% for mental health conditions), consultation of a medical specialist in 7% (often for chronic 
medical conditions), and non-pharmaceutical treatments in 6%.  
Changes in environmental circumstances occurred in 68 participants. The mean number of changes 
between baseline and 40 weeks was 1.3. Mostly tThe changes were mostly in daily activities, in 
composition of the residential group, in the main caregiver, and moving to a new residence.  
 
Differences between groups achieving complete and incomplete discontinuation  
Participants who had achieved complete discontinuation had a less severe intellectual disability, less 
often presence of autism and chronic neurological conditions, less severe parkinsonism, had less 
often worsening in health during the study period, and had more often a history of dermatoses and 
surgical conditions; with regard to psychotropic drug use they used a lower baseline dosage,  and 
used less often > 1 antipsychotic simultaneously and had less severe parkinsonism. They also 
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experienced fewer severe behavioral symptoms as measured with the ABC. See Supplemental table 2 
for all differences between participants with complete versus those with incomplete discontinuation 
at the time points 16, 28, and 40 weeks after the first dose reduction.  
 
Determinants of successful discontinuation at the time points 16, 28, and 40 weeks 
We found aA number of participant characteristics and determinants which were associated with the 
chance of complete discontinuation at the different time points. No history of dermatoses, no history 
of surgical conditions, no stressful family conditions, higher dose of antipsychotic drug, higher scores 
of ABC, and higher scores of akathisia were all associated with a lower chance of complete 
discontinuation. The aAbsence of autism, no recent hospitalization, and no use of more than on 
antipsychotic drug simultaneously were associated with higher chance of complete discontinuation. 
Furthermore, more frequent worsening in health during discontinuation was associated with lower 
chance of complete discontinuation. 
Table 3 presents the results of multivariate logistic regression analyses at the different time points, 
with. Here, the achievement of complete discontinuation ais the dependent variable. As independent 
variables we included those variables with p-values <0.1 in univariate analyses (see Supplemental 
table 3) 
Because we were interested in the influence of neurological (withdrawal) symptoms on the severity 
of challenging behavior we also investigated potential associations of extrapyramidal and autonomic 
symptoms with ABC subscales. We found that hHigher ratings of ABC subscale lethargy were 
associated with more severe akathisia and autonomic dysregulation, and higher ratings of ABC 
subscale stereotypy and of ABC subscale hyperactivity with more severe dyskinesia, akathisia, and 




Page 30 of 49
http://mc.manuscriptcentral.com/jocp
































































In this open label discontinuation study we found that 61% of participants were able to discontinue 
off-label antipsychotics completely in 16 weeks. At follow-up, three months later, (28 weeks after the 
first dose reduction) 46% of participants were still completely off their antipsychotic medication, and 
at 40 weeks follow-up 40%. These results are within the range ofin line with other discontinuation 
studies
76
 and but somewhat better than those in our previous study in which 43% succeeded 




The severity of behavioral symptoms as assessed with the ABC total and subscales had decreased in 
those participants who were completely off medication at all three different time points, but and had 
not changed significantly in those who had not achieved full discontinuation. These results also 
confirm our previous findings of improveddecrease in severity of behavioral symptoms as measured 
with the ABC in those achieving complete discontinuation and on average no change in those with 
incomplete discontinuation confirm our previous findings
12
. Furthermore, in general, in both groups 
there were individual participants with an increase andor decrease in severity of behavioral 
symptoms during discontinuation. We found it was not the difference in severity, but the severity of 
symptoms itself which was related to the chance of complete discontinuation. 
Results Wwith regard to the course severity of neurological symptoms of side-effects were found 
mixed results. On the one hand there was a decrease in parkinsonism in those with complete 
discontinuation, on the other hand a decrease in akathisia in those with incomplete discontinuation 
at 40 weeks. Furthermore, autonomic symptoms had increased in those having incompletely 
discontinued at 16 weeks. The decrease in akathisia in those participants who still used antipsychotic 
drugs may be explained by the potential of these agents to mask this extrapyramidal symptom or by 
the disappearance of withdrawal akathisia
132
 . Furthermore, aAutonomic symptoms had increased in 
those having incompletely discontinued at 16 weeks. Thise increase in autonomic symptoms may 
have been caused by again increasing the dosage increases or additional prescriptions of 
psychotropic drugs following the behavioral disturbances which had led to termination of the 
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discontinuation trajectory. Overall, with the exception of parkinsonism the severity of extrapyramidal 
and autonomic symptoms did not differ between participants who achieved complete versus 
incomplete discontinuation. This may be caused by the nature of dyskinesia and akathisia, symptoms 
of which may persist for long periods or may even be irreversible, and by already present or 
emerging autonomic symptoms caused by comorbid medical conditions.  
 
 Although a substantial proportion of participants succeeded in completely tapering off their 
antipsychotic drug use, at follow-up the majority of participants had failed to do so. In tThe present 
study we foundindicated some determinants which might help to predict the failureswhether 
discontinuation will be successful. The presence of autism, akathisia, higher ABC scores, and more 
frequent worsening in health during discontinuation were clearly associated with lower odds of 
successful discontinuation. In people with intellectual disability co-morbid mental disorders, 
neurological side-effects of antipsychotics and ill-health conditions may express in as behavioral 
symptoms, which may be difficult to manage. Indeed, more severe dyskinesia, akathisia, and 
autonomic symptoms were associated with higher scores on the ABC subscales lethargy, stereotypy, 
and hyperactivity. Moreover, wWhen underlying causes of maladaptive behaviors are not 
recognized, appropriate treatments will be lacking, and the severity of behavioral symptoms may 
increase, . Furthermore, since we found that more severe dyskinesia, akathisia and autonomic 
symptoms were associated with higher scores of ABC subscales lethargy, stereotypy and 
hyperactivity these symptoms which in turn may also hinder successful discontinuation.  
Remarkably was the finding of the association between a history of dermatoses and of surgical 
disorders, and stressful family conditions with a higher chance of successful discontinuation. This 
may be explained by the nature of these disorders/circumstances. Although these conditions may 
lead to behavioral worsening, these will be easily recognized and will be no reason for continued use 
of antipsychotics.    
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We could not confirm tThe commonly accepted idea that changes in environmental circumstances 
should be a reason not to start or even to stop antipsychotic discontinuation trajectories could not 
be confirmed, since we did not find angiven no association of between changes in living 
circumstances and life events with lower chance for of successful discontinuation.  
 
Strengths and limitations 
 
A strength of the present study was that it reflects discontinuation in clinical practice. We accounted 
fortook the influence of negative changes in health conditions and environmental circumstances into 
consideration. However, recruitment of participants was difficult. In only half of cases physicians 
judged their clients with off-label antipsychotic drug use were eligible to discontinue, and of those 
just 26% consented to participate in the study. Fear of clinicians, caregivers, and legal representatives 
for behavioral worsening were main reasons not to discontinue. McNamara et al (2017)
143
 also 
encountered major recruitment problems in their double blind randomized controlled 
discontinuation trial of risperidone used for challenging behaviors. They suggested that lack of 
alternative behavioral interventions to manage the potential re-emergence of challenging behaviors 
of clients may be reasons for the poor recruitment. 
Another limitation of this study was that there were missing data which reduced the available cases 
for multivariate analyses. Therefore, the results of this study with regard to factors associated with 
successful discontinuation of long-term used antipsychotic drugs should be confirmed in larger scale 
studies. However, the sample size was large enough to assess associations in univariate analyses 
reliably and we think these results have clinical importance and will add to the knowledge in ongoing 
off-label antipsychotic drug use in people with intellectual disability. The open label study design is 
another limitation, although it does reflect discontinuation in clinical practice which is also typically 
open label. Also, we did notno correction for multiple testing was done, to reduce the risk of type 2 
errors. ThereforeHowever, we cannot exclude that some results may have been spurious. Last, 
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because the study took place in living facilities of congregated care centers, in a selected sample, the 
results may not be generalizable to people with intellectual disability who live in the community and 
to clients not eligible to discontinue according to their clinicians’ judgements. However, our results 
have clear implications with regard to health care for those who use long-term off-label 
antipsychotics and these implications apply for community mental health care workers and general 
practitioners as well. 
 
CONCLUSIONS/CLINICAL AND RESEARCH IMPLICATIONS 
Forty percent of participants with intellectual disability who had been declared were judged suitable 
by their responsible clinicians to be eligible for a trial of withdrawal trial of their long-term off-label 
antipsychotic drugs were able to discontinue in a time frame of approximately four to seven months 
with on average no behavioral worsening.  
We identified some a number determinants, which may explaining the failure of to achieve complete 
discontinuation of long-term off-label used antipsychotics in people with intellectual disability and 
these findings should havewith clear clinical implications. Especially worsening in chronic medical 
conditions or temporary ill-health conditions in clients, which were negatively associated with 
successful discontinuation should be addressed appropriately and should be no reason to stop the 
discontinuation trajectory. Also, the presence of neurological side-effects symptoms should be 
carefully examined and appropriately managed, since these symptoms were associated with higher 
severity of maladaptive behavior, which in turn was associated with more a higher chance of failure 
failedin discontinuation of antipsychotics. Finally, the presence of autism spectrum disorder, which 
was also associated with failedure in discontinuation, should be a reason to carefully look for 
comorbid psychosis or symptoms of other mental disorders, since comorbidity of mental disorders is 
common in this group of patients.perhaps indicating that antipsychotics are more effective in those 
with autism spectrum disorder. 
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Because just over 25% of eligible participants took part in the study, we ought to be cautious in 
drawing final conclusions as results may not be generalizable to the whole population using long 
term antipsychotics; however, this low percentage of those willing to attempt discontinuation 
reflects clinical reality. Larger scale studies in various settings of intellectual disability care are 
needed to confirm our results and to investigate which treatments should be offered in case of 
unsuccessful attempts to discontinue off-label antipsychotics. 
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Figure 1: Flow chart of the study 
*according to physicians judgement; 
#
main reasons for non-inclusion were clinicians’ concerns that 
discontinuation might be harmful due to changes in the clients’ environment  
Figure 2 
Figure 2: Flow chart of antipsychotic drugs discontinuation trajectory of participants  
#
16 weeks: one participant had died; 28 weeks: two participants had died; 40 weeks: two participants 
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Figure 2: Flow chart of antipsychotic drugs discontinuation trajectory of participants  
#16 weeks: one participant had died; 28 weeks: two participants had died; 40 weeks: two participants had 
died and of eight participants clinicians failed to provide data  
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Table 1a Characteristics of participants (n=129) with intellectual disability who will discontinue long-term use of 
antipsychotics for behavioral symptoms 
Age in years
*
, median, mean (SD) 
 
51.3, 49.2 (16.0); (range 11.5-84.2) 
Sex, male  66.7% 
Severity of intellectual disability
1




Living situation Congregated centre: 70.9% 
Community centre : 22.2% 
Community living facility: 6.8% 
Living situation, group size 1-4 persons; 18.5% 
4-8 persons: 55.6% 
8-12 persons: 22.2% 
Independently: 3.7% 





Presence of comorbid non-psychotic mental conditions Autism spectrum disorder: 67.4% 
ADHD: 3.6% 
Mood disorder:7.3% 
Post-Traumatic Stress Disorder: 0.9% 
Anxiety disorder: 5.5% 
Obsessive compulsive disorder: 0.9% 
Attachment disorder: 3.6% 










 : 23.8% 
Mean scores of those with EPS symptoms
4,6
 (n=60) (SD) 9.2 (5.7), minimum 3, maximum 28 



















Mean scores of those with autonomic symptoms
4,7 
(n=87) (SD) 13.5 (8.4), minimum 3, maximum 35 
 
*
 including three adolescents  
1
 as noted in the medical record; 
2









 EPS: as measured with the Abnormal Involuntary Movement Scale items 1 through 9, BARS akathisia 
objective symptoms,  subjective symptoms and burden scale and Unified Parkinson Disorder Rating Scale 
motor items 20, 21, 22 and 31 (maximum scale score=41); 
7 
autonomic symptoms: as measured with the 
adapted Scale Outcomes Parkinson-autonomic symptoms (maximum scale score=61) 
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Table 1b Psychotropic drug use of participants (n=129) with intellectual disability who will discontinue long-
term use of antipsychotics for behavioral symptoms 
Defined Daily Dose of total antipsychotic drug use, mean (SD) 0.60 (0.48) 
Defined Daily Dose of users of atypical antipsychotics,  mean (SD) 0.67 (0.46) 
Defined Daily Dose of users of typical antipsychotics,  mean (SD) 0.55 (0.48) 




























Use of >1 antipychotic drug simultaneously (%) 7.4 
Use of other psychotropic drugs (%) 31.1 
Use of anticonvulsive drugs (%) 36.1 
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Table 2  
Differences in scores of Aberrant Behavior Checklist (ABC) between participants who had completely (n=79) 
and who had incompletely (n=49) discontinued  long-term off-label use of antipsychotics at the time point of 16 














ABC total 33.6/52.7 29.0/43.0 27.5-39.7/41.2-
64.2 
p=0.01 
ABC subscale irritability 10.9/16.85 8.0/14.0 8.6-13.1/13.1-20.6 p=0.02 
ABC subscale lethargy 6.6/9.3 4.0/7.5 4.8-8.3/6.8-11.8  
ABC subscale stereotypy 4.5/6.5 3.0/5.5 3.3-5.7/4.7-8.3 p=0.04 
ABC subscale 
hyperactivity 
9.1/15.9 7.0/12.5 7.2-11.0/12.1-19.7 p=0.005 
ABC subscale inadequate 
speech 
2.6/4.2 2.2/4.0 1.8-3.3/3.0-5.5  
 
#
 Subscale 1=irritability, - 2= lethargy, - 3= stereotypy; - 4= hyperactivity, -5= inadequate speech 
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Table 3  
Odds
#
 of achievement of complete discontinuation of long-term off-label used antipsychotics in 
people with intellectual disability (n=129) at the time point of 16 weeks (discontinuation per 
protocol), 28, and 40 weeks after the first dose reduction 
 Determinants Odds Ratio (OR) 
(95% Confidence 
Interval) 


































No history of 
surgical 
conditions 






















 In multivariate logistic regression analyses 
* 
Hosmer and Lemeshow Test; percentage of correct prediction of “no achievement of complete 
discontinuation”/percentage of correct prediction of “achievement of complete discontinuation”, 
and percentage of overall correct prediction 
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Table 4  
Associations of neurological extrapyramidal and autonomic symptoms
1
 with behavioral symptoms as measured 
with the Aberrant Behavior Checklist at different time points during and after discontinuation trajectories 
 
 baseline 16 weeks 28 weeks 40 weeks 
ABC subscale 
irritability 




















ABC subscale  
stereotypy 
Dyskinesia 































  Autonomic 
symptoms 






    
 
1
 Dyskinesia as measured with the 
 
Abnormal Involuntary Movement Scale items 1 through 9; akathisia with the 
Barnes akathisia objective symptoms,  subjective symptoms and burden scale; parkinsonism with the Unified 
Parkinson Disorder Rating Scale motor items 20, 21, 22 and 31; autonomic symptoms with the adapted Scale 
Outcomes Parkinson-autonomic symptoms 
ABC= Aberrant Behavior Checklist 
β: standardized regression coefficient 
R 
2
: adjusted R square; explained variance 
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AN OPEN LABEL DISCONTINUATION TRIAL OF LONG-TERM USED OFF-LABEL ANTIPSYCHOTIC MEDICATION IN PEOPLE WITH 
INTELLECTUAL DISABILITY; DETERMINANTS OF SUCCESS AND FAILURE 
Gerda M. de Kuijper & Pieter J. Hoekstra 
 
Supplemental Table 1  
Comparisons of severity of behavioral and physical symptoms associated with use of antipsychotic drugs in 
people with intellectual disability (n=129) for groups of participants who had completely and incompletely 
discontinued their long-term off-label use between baseline and 16 weeks (discontinuation as per protocol), 28 
and 40 weeks after the first dose reduction 















































40.7 (24.8)/42.2 (32.3) 
ABC
1






12.0 (8.6)/11.0 (9.8)  
 
12.8 (9.8)/16.6 (12.7)  
 
12.6 (8.7)/10.4 (9.4) 
 







12.0 (9.2)/12.6 (10.8) 
ABC
1





















10.2 (8.2)/8.9 (8.9) 
ABC
1






4.6 (4.5)/4.3 (5.2) 
 
4.8 (4.2)/6.5 (6.0) 
 
4.4 (4.8)/3.4 (4.5) 
 
5.2 (4.2)/6.2 (5.5)/ 
 
4.5 (5.0)/3.9 (4.5) 
 
5.0 (4.3)/5.0 (4.8) 
ABC
1






9.6 (7.3)/9.0 (8.3) 
 
12.6 (8.6)/15.9 (12.8) 
 
10.0 (7.4)/8.6 (8.3) 
 






10.9 (8.2)/12.3 (10.1) 
ABC
1






2.7 (3.1)/2.5 (3.2) 
 
3.1 (3.5)/4.2 (4.2) 
 
2.5 (3.2)/2.5 (3.4) 
 
3.4 (3.3)/4.5 (3.8) 
 
2.4 (3.3)/1.8 (2.7) 
 









3.6 (5.1)/3.8 (5.0) 
 
3.1 (5.1)/3.7 (6.0) 
 
3.4 (4.9)/3.4 (5.0) 
 
3.6 (5.3)/3.4 (4.9) 
 
4.2 (6.0)/3.7 (5.3) 
 









1,0 (1.6)/1.1 (1.9) 
 
1.1 (2.0)/1.1 (1.6) 
 
0.9 (1.2)/0.7 (1.2) 
 
1.3 (2.1)/1.4 (1.9) 
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4.9 (5.3)/5.7 (7.0) 
 
5.4 (7.2)/6.0 (7.8) 
 
4.8 (5.4)/4.4 (5.5) 
 
5.8 (6.7)/6.1 (7.1) 
 
5.1 (5.9)/11.3 (8.4) 
 















11.1 (8.1)/11.7 (9.7) 
 
12.6 (9.6)/13.1 (8.7) 
 
11.7 (8.5)/11.2 (8.2) 
 
11.8 (9.1)/12.4 (9.2) 
 
1 
Aberrant behavior Checklist; total and subscales 1 (irritability), - 2 (lethargy), - 3 Stereotypy, - 4 (hyperactivity) 
and - 5 (inadequate speech); 
2 
Abnormal Involuntary Movement Scale items 1 through 9; 
3
 Barnes akathisia 
objective symptoms,  subjective symptoms and burden scale; 
4
 Unified Parkinson Disorder Rating Scale motor 
items 20, 21, 22 and 31; 
5
 Total of scores of extrapyramidal symptoms as measured with the AIMS, BARS and 
UPDRS; 
6
 total of autonomic symptoms as measured with the adapted Scale Outcomes Parkinson-autonomic 
symptoms 
* 
 Paired samples within groups: Significant difference according to Wilcoxon Signed rank test  
(hyperactivity) and - 5 (inadequate speech 
*
1
 one participant had died; *
2
 two participants had died; *
3
 two participants had died and data of ten 
participants missing due to clinicians failing to provide data  
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Gerda M. de Kuijper & Pieter J. Hoekstra 
 
Supplemental Table 2: Differences between groups of participants with intellectual disability who had 
completely and incompletely discontinued their long-term off-label use of antipsychotics at 16 weeks 
(discontinuation as per protocol), 28 and 40 weeks (follow-up) after the first dose reduction 














discontinuation 40 weeks 


































Presence of neurological 
conditions (including 
sensory impairment) (%) 

















Dose of antipsychotic 









Use of >1 antipsychotic 
drug simultaneously (%) 























Event of worsening in 
health (range 0-6/4 
weeks) 
Baseline-16 weeks 
16-28 weeks (mean/SD) 
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 1-4: profound=1, severe=2, moderate=3, mild=4; 
2 
Unified Parkinson Disorder rating Scale; motor items 20, 
21, 22 and 31; 
3 
Aberrant Behavior Checklist; total and subscales 1 (irritability), - 2 (lethargy), - 3 Stereotypy, - 4 
(hyperactivity) and - 5 (inadequate speech 
*
1
 one participant had died; *
2
 two participants had died; *
3
 two participants had died and data of ten 
participants missing due to clinicians failing to provide data  
&
 Independent samples Mann-Whitney U test. 
$
 t-test; a negative value of t relates to incomplete 
discontinuation;  
Significant difference is defined for p-values of <0.05.  
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INTELLECTUAL DISABILITY; DETERMINANTS OF SUCCESS AND FAILURE 
Gerda M. de Kuijper & Pieter J. Hoekstra 
 
Supplemental Table 3: Determinants/baseline characteristics in univariate regression analyses for successful 
discontinuation of long-term off-label used antipsychotic drugs in people with intellectual disability (n=129) at 
16 weeks (per protocol), 28 and 40 weeks (follow-up) after the first dose reduction. 
Determinants 16 weeks  28 weeks 40 weeks 









Less severe intellectual 
disability 
OR=1.48; 0.05<p<1.0   
No history of surgical 
conditions 









   











   




   







Worsening in health 
/28-40 weeks 
  OR=0.68; p<0.05
#
 
Worsening in health /0-
40 weeks 
  OR=0.79; p<0.01
#
 





 OR=6.71; 0.05<p<0.1 




 OR=0.49; 0.05<p<0.1 
Larger living group size  OR=1.55; 0.05<p<1.0 OR=1.53; 0.05<p<0.1 
ABC
3





















 at 16 weeks   OR=0.77; p=0.05
#
 







 at 40 weeks   OR=0.80; <0.05p<0.1 
 
1
 Odds ratio 
2
 significance level p-value <0.05; 
#
 Significant association 
3
 Aberrant Behavior Checklist (ABC); range 0-174 
4 
Barnes akathisia objective symptoms, subjective symptoms and burden scale; range 0-9.  
5
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